Regional Business Manager - Mountain

Why Join Intellia? Our mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. Beyond our science, we live our four core values: One, Explore, Disrupt, Deliver and feel strongly that you can achieve more at Intellia. We have a single-minded determination to excel and succeed together. We believe in the power of curiosity and pushing boundaries. We welcome challenging thoughts and imagination to develop innovative solutions. And we know that patients are counting on us to make the promise a reality, so we must maintain high standards and get it done. We want all of our people to go beyond what is possible. We aren’t constrained by typical end rails, and we aren’t out to just “treat” people. We’re all in this for something more. We’re driven to cure and motivated for change. Just imagine the possibilities of what we can do together. How You Will Achieve More: We are seeking an exceptional Sales Representative to lead the commercial launch of our groundbreaking in vivo CRISPR therapy for hereditary angioedema (HAE). This role represents a career defining opportunity to pioneer the commercialization of the first-ever, single treatment gene editing therapy. The successful candidate will be responsible for introducing healthcare providers to the first-ever in vivo CRISPR therapy, requiring sophisticated scientific communication, complex stakeholder management, and exceptional execution within a highly competitive rare disease market. This territory will cover Nevada, Utah, Idaho, Montana and Wyoming. Responsibilities: Territory Management & Account Development Territory Planning: Develop and execute comprehensive territory plans targeting immunologists, allergists, emergency medicine physicians, and specialized HAE treatment centers Account Prioritization: Identify and prioritize high-value accounts based on HAE patient volume, prescriber influence, and institutional capabilities Relationship Building: Establish trusted advisor relationships with key opinion leaders, clinical champions, and administrative decision-makers Pipeline Management: Maintain robust sales pipeline tracking opportunities from initial awareness through patient treatment completion Scientific Education & Communication CRISPR Technology Education: Educate healthcare providers on in vivo CRISPR gene editing mechanisms, differentiating from ex vivo cell therapies and traditional treatments MOA Differentiation: Clearly articulate the unique mechanism of action compared to prophylactic treatments, complement inhibitors, and plasma-derived therapies Clinical Data Presentation: Present Phase III efficacy and safety data Technology Positioning: Address misconceptions about CRISPR safety and differentiate from previous gene therapy launches Disease Education: educate healthcare providers about unmet needs affecting disease management and treatment burden Competitive Differentiation Competitive Intelligence: Maintain deep understanding of competitive landscape and emerging therapies Value Proposition Development: Articulate differentiated value propositions versus existing HAE treatments and other gene therapies Objection Handling: Proactively address concerns about CRISPR technology, permanent genetic modification, and single-treatment cost **Company Differentiation**: Position organization as innovative leader with superior clinical acumen Complex Treatment Pathway Management Patient Journey Education: Educate on the patient pathway from diagnosis confirmation through treatment administration Hub Services Integration: Coordinate with patient support hubs to ensure seamless patient experience and treatment access Cross-Functional Collaboration Medical Affairs Partnership: Coordinate with Medical Science Liaisons to seamlessly address customers’ medical and clinical informational needs Market Access Alignment: Work closely with Field Reimbursement Managers on payer strategy and coverage optimization Strategic Accounts: Partner with strategic accounts team to understand referral patterns, site selection, and site activation for procurement and administration of the therapy About You: Scientific & Technical Knowledge HAE Understanding: Comprehensive knowledge of hereditary angioedema pathophysiology, treatment landscape, and unmet medical needs CRISPR/Gene Therapy Familiarity: Understanding of gene editing technologies, genetic medicines, and regulatory requirements **Clinical Data Interpretation**: Ability to analyze and present complex clinical trial data and real-world evidence Skills & Competencies Scientific Communication: Exceptional ability to communicate complex scientific concepts to diverse healthcare audiences Customer Alignment & Relationship Management: Proven ability to build and maintain long-term relationships with key stakeholders Problem Solving: Creative approach to overcoming access barriers and treatment implementation challenges Collaboration and Learning: nurtures internal relationships and facilitates collaboration to establish trust and support from others. Growth Mindset: Remain open to change and demonstrates a willingness to try new approaches to achieve better results Competitive Mindset: Engages in bold conversations, handles objections, and asks for the business Execution and Results: Demonstrates a business owner mindset and takes action to exceed expectations. Develops and executes on a comprehensive business plan to maximize customer and patient impact Personal Attributes Innovation Mindset: Passion for pioneering new treatment paradigms and improving patient outcomes Resilience: Ability to persist through lengthy sales cycles and overcome technology-related objections Adaptability: Flexibility to adjust strategies based on market feedback and competitive dynamics Integrity: Unwavering commitment to ethical sales practices and regulatory compliance Patient Focus: Genuine commitment to improving lives of patients with rare genetic diseases BS/BA in life sciences or a business-related field Rare Disease, Gene therapy, and HAE market knowledge preferred but not necessary Sales Experience: 5+ years of specialty pharmaceutical sales experience, preferably in rare diseases, immunology, or genetic medicines Rare Disease Expertise: Proven track record in rare disease commercialization with complex treatment paradigms and small patient populations Launch Experience: Previous experience with product launches, particularly first-in-class or novel mechanism therapies Complex Sales Environment: Demonstrated success in long sales cycles (12-18 months) with multiple stakeholders and high-value transactions #LI-Remote EEOC Statement: Intellia believes in a diverse environment, and is committed to equal employment opportunity for all its employees and qualified applicants. We do not discriminate in recruitment, hiring, training, promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. Intellia will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law. Applications are accepted on a rolling basis, and will continue to be accepted until the position is filled at which point the position will be taken down. The base salary for this position is expected to range between $166,500.00 - $203,500.00 USD per year. The salary offered is determined based on a range of factors including, but not limited to, relevant education and training, overall related experience, specialized, rare or in-demand skill sets, internal comparators and other business needs. Upon joining Intellia, your salary will be reviewed periodically and additional factors such as time in role and performance will be considered. Intellia may change the published salary range based on company and market factors. Additional compensation includes a performance-based annual cash bonus, a new hire equity grant, and eligibility to be considered for annual equity awards the value of which are determined annually at the Company’s discretion. For more information about Intellia’s benefits, please click here. At Intellia, we are committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to create novel engineered cell therapies for immuno-oncological and autoimmune diseases.